Daniyal Muhammad, Polani Anamm, Kumar Amrat, Raja Ahmad, Canary Marcy
Internal Medicine, Bassett Medical Center, Cooperstown, USA.
Hematology and Medical Oncology, Bassett Medical Center, Cooperstown, USA.
Cureus. 2025 May 28;17(5):e84943. doi: 10.7759/cureus.84943. eCollection 2025 May.
Composite lymphoma (CL) is a rare and diagnostically challenging condition where two or more distinct types of lymphoma coexist within the same anatomical site. We report the case of an 82-year-old man with a history of low-grade B-cell lymphoma, now presenting with recurrent disease characterized by a composite histology of marginal zone lymphoma (MZL) and classic Hodgkin's lymphoma (CHL). Management involved single-agent brentuximab due to comorbidities, followed by immune checkpoint inhibition upon relapse. This case illustrates key considerations in the diagnosis, staging, and treatment of CLs in geriatric patients. The clinical course further highlights the importance of personalized therapy selection based on age, comorbidities, and histological features. This case also contributes to the limited literature on real-world outcomes in patients with CL and underscores the need for future prospective studies and biomarker-driven treatment approaches in this rare entity.
复合淋巴瘤（CL）是一种罕见且诊断具有挑战性的疾病，其中两种或更多不同类型的淋巴瘤在同一解剖部位共存。我们报告了一例82岁男性病例，其既往有低度B细胞淋巴瘤病史，目前复发疾病表现为边缘区淋巴瘤（MZL）和经典霍奇金淋巴瘤（CHL）的复合组织学特征。由于合并症，治疗采用单药brentuximab，复发后采用免疫检查点抑制治疗。该病例说明了老年患者CL诊断、分期和治疗中的关键考虑因素。临床过程进一步凸显了根据年龄、合并症和组织学特征进行个性化治疗选择的重要性。该病例也为CL患者真实世界结局的有限文献做出了贡献，并强调了未来对这一罕见实体进行前瞻性研究和生物标志物驱动治疗方法的必要性。
